@orlysgrrl's GLP-1 claims about side effects, fact-checked
Quick answer
GLP-1 receptor agonists like semaglutide and tirzepatide have receptors in limbic brain regions, and emerging data suggest some users experience emotional blunting, mood shifts, or changes in interpersonal dynamics during treatment. The FDA conducted a safety review of suicidality signals for semaglutide in 2023 without confirming causality, but the review remains active. Patients reporting emotional changes on GLP-1 therapy should discuss symptoms with their prescriber rather than self-adjusting medication.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @orlysgrrl actually say?
The clip is brief and decontextualized. @orlysgrrl says: "So do you not know that I have feelings or do you just not care that I have feelings?" That's the entirety of the transcript. Without the reply video from @michelle_motor_city that prompted this, we're reading tea leaves here. But the GLP-1 category tag and the emotional framing make the implied subject pretty clear: emotional blunting, mood changes, or interpersonal friction that users commonly attribute to semaglutide or tirzepatide.
This appears to be a personal expression of emotional distress, possibly related to how a relationship or support system has responded to the creator's GLP-1 experience. It is not a medical claim. It's a feeling. And feelings, it turns out, are actually a documented and underexplored dimension of GLP-1 pharmacology.
Does the science back this up?
Yes, partially, and more than the FDA's current labeling reflects. There is growing clinical interest in how GLP-1 receptor agonists affect mood, emotional processing, and interpersonal dynamics. A 2023 pharmacovigilance analysis published in eClinicalMedicine (Kose et al.) identified signals for depression and suicidal ideation in the FDA Adverse Event Reporting System for semaglutide users, though causality remains unestablished.
Separately, GLP-1 receptors are expressed in limbic brain regions including the amygdala and hippocampus, areas involved in emotional regulation. Animal studies from Kanoski et al. (2016, Neuropharmacology) showed that GLP-1 receptor activation in the brain influences reward processing and anxiety-like behavior. Human data are limited but emerging. What clinicians are seeing anecdotally, and what patients are posting about, is a flattening of emotional reactivity that some find distressing and others find stabilizing. The science does not yet explain which patients experience which outcome, or why.
What did they get wrong (or right)?
@orlysgrrl did not make a false medical claim, so there's nothing to correct on that front. What's worth naming, though, is the broader pattern this clip fits into: people on GLP-1 medications experiencing emotional shifts that their social circles don't recognize or take seriously.
That's real, and it's documented. Research on weight loss and identity disruption, including work by Pratt et al. (2023, Obesity), shows that rapid body composition changes can destabilize personal relationships and self-perception in ways that the prescribing encounter rarely addresses. The emotional experience of being on a GLP-1 drug is not just about nausea and injection schedules. It involves changes in how people relate to food, pleasure, reward, and sometimes to other people.
What's missing from this clip, not a criticism of the creator but a gap worth flagging, is any connection to whether GLP-1 pharmacology might be contributing to whatever emotional friction she's describing. That's a conversation worth having with a prescriber, not just a TikTok audience.
What should you actually know?
If you're on a GLP-1 medication and noticing mood changes, emotional blunting, or shifts in how you relate to the people around you, you're not imagining it and you're not alone. This is an underreported side effect category, and the research is still catching up to what patients have been saying for two years.
The FDA added a safety review for suicidality signals to semaglutide in 2023, though the agency's preliminary conclusion was that evidence did not confirm causality. That review is ongoing. Liraglutide has longer safety data and does not carry the same signal at comparable intensity, but all GLP-1 drugs share the same receptor mechanism in brain tissue.
If you are experiencing significant mood changes, talk to your prescriber before adjusting your dose or stopping the medication. Abrupt discontinuation of GLP-1 therapy has its own documented effects on appetite and weight rebound, and a prescriber needs to weigh those against mood symptoms case by case. This is not a reason to avoid these medications. It is a reason to take the full picture of your experience seriously and to expect your prescriber to do the same.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @orlysgrrl's GLP-1 claims about side effects, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@orlysgrrl's GLP-1 claims about side effects, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
GLP-1 receptor agonists like semaglutide and tirzepatide have receptors in limbic brain regions, and emerging data suggest some users experience emotional blunting, mood shifts, or changes in interpersonal dynamics during treatment.
FormBlends verdict
GLP-1 receptor agonists like semaglutide and tirzepatide have receptors in limbic brain regions, and emerging data suggest some users experience emotional blunting, mood shifts, or changes in interpersonal dynamics during treatment. The FDA conducted a safety review of suicidality signals for semaglutide in 2023 without confirming causality, but the review remains active. Patients reporting emotional changes on GLP-1 therapy should discuss symptoms with their prescriber rather than self-adjusting medication.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide and tirzepatide have receptors in limbic brain regions, and emerging data suggest some users experience emotional blunting, mood shifts, or changes in interpersonal dynamics during treatment. The FDA conducted a safety review of suicidality signals for semaglutide in 2023 without confirming causality, but the review remains active. Patients reporting emotional changes on GLP-1 therapy should discuss symptoms with their prescriber rather than self-adjusting medication.
- GLP-1 receptors are present in limbic brain regions; Kanoski et al. (2016, Neuropharmacology) showed receptor activation affects reward and anxiety-like behavior in animal models.
- The FDA issued a safety communication in 2023 reviewing suicidality signals for semaglutide; preliminary findings did not confirm causality, but the review is ongoing.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- GLP-1 receptors are present in limbic brain regions; Kanoski et al. (2016, Neuropharmacology) showed receptor activation affects reward and anxiety-like behavior in animal models.
- The FDA issued a safety communication in 2023 reviewing suicidality signals for semaglutide; preliminary findings did not confirm causality, but the review is ongoing.
- A 2023 eClinicalMedicine pharmacovigilance analysis (Kose et al.) identified depression and suicidal ideation signals in GLP-1 FAERS data, though these are hypothesis-generating, not conclusive.
- Emotional blunting and mood flatness are among the most commonly reported but least clinically documented subjective side effects of semaglutide and tirzepatide.
- Rapid body composition changes from GLP-1 therapy can disrupt personal relationships and self-identity in ways that prescribers rarely address, per Pratt et al. (2023, Obesity).
- Patients experiencing mood changes on GLP-1 medications should not self-discontinue; abrupt cessation is associated with appetite rebound and weight regain and requires a managed clinical approach.
- The emotional experience of GLP-1 therapy, including changes in food-related reward and interpersonal dynamics, is a legitimate clinical topic that deserves more than a brief side-effect checklist at the prescribing visit.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Jana Marie · TikTok creator
316.5K views on this video
Replying to @michelle_motor_city
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Jana Marie, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.